TY - JOUR
T1 - Psychophysiological responses to group cognitive-behavioral therapy in depressive patients
AU - Varela, Yves Martins
AU - de Almeida, Raíssa Nóbrega
AU - Galvão, Ana Cecília de Menezes
AU - de Sousa Jr, Geovan Menezes
AU - de Lima, Ana Cecília Lopes
AU - da Silva, Neuciane Gomes
AU - Leocadio-Miguel, Mario André
AU - Lobão-Soares, Bruno
AU - Hallak, Jaime Eduardo Cecílio
AU - Maia-de-Oliveira, João Paulo
AU - Galvão-Coelho, Nicole Leite
N1 - Funding Information: This study was funded by National Science and Technology Institute for Translational Medicine (INCT-TM Fapesp 2014/50891–1; CNPq 465458/2014–9). NLGC is supported by CAPES Foundation from Brazilian Ministry of Education (Research Fellowship 88887.466701/2019–00) National Science and Technology Institute for Translational Medicine (INCT-TM Fapesp 2014/50891–1; CNPq 465458/2014–9). The funder did not have any role in the design of the study, collection, analysis, and interpretation of data and in drafting the manuscript.
PY - 2023/1/1
Y1 - 2023/1/1
N2 - Cognitive-Behavioral Therapy (CBT) has a significant adjunctive effect in the treatment of Major Depressive Disorder (MDD), however its use as monotherapy in group-based approaches is less explored. We assessed the responses of distinct psychophysiological domains after a group-based CBT (gCBT, 16 weeks) intervention in drug-free patients with mild-moderate MDD (n = 20; women = 11) and compared them with a healthy control group (n = 25, women = 13). The treatment resulted in 65% of response and 55% of remission rates. Significant reductions in depressive and anxiety symptoms and increase in self-esteem and sleep quality were observed as gCBT responses. Moreover, after treatment, patients regulated their previously deregulated salivary cortisol awakening response and sleep quality toward healthy parameters. These improvements were correlated among themselves and dependent of remission outcome. Remitted patients showed larger improvements than non-remitted for all psychophysiological domains, except for serum cortisol that significantly changed only for no-remitted patients after gCBT but did not reached controls levels. Further, better baseline sleep quality was predictor of remission. The psychophysiological changes found support the use of gCBT as monotherapy treatment for mild-moderate MDD, corroborate the importance of the observation of the patients in theirs whole sociopsychophysiological condition since they are related to remission outcome and then stimulate further studies of validation of clinical protocols that work on all of these psychophysiological domains studied. Trial Registration U1111–1215-4472. Registered 21 August 2018, http://www.ensaiosclinicos.gov.br/rg/RBR-3npbf8/.
AB - Cognitive-Behavioral Therapy (CBT) has a significant adjunctive effect in the treatment of Major Depressive Disorder (MDD), however its use as monotherapy in group-based approaches is less explored. We assessed the responses of distinct psychophysiological domains after a group-based CBT (gCBT, 16 weeks) intervention in drug-free patients with mild-moderate MDD (n = 20; women = 11) and compared them with a healthy control group (n = 25, women = 13). The treatment resulted in 65% of response and 55% of remission rates. Significant reductions in depressive and anxiety symptoms and increase in self-esteem and sleep quality were observed as gCBT responses. Moreover, after treatment, patients regulated their previously deregulated salivary cortisol awakening response and sleep quality toward healthy parameters. These improvements were correlated among themselves and dependent of remission outcome. Remitted patients showed larger improvements than non-remitted for all psychophysiological domains, except for serum cortisol that significantly changed only for no-remitted patients after gCBT but did not reached controls levels. Further, better baseline sleep quality was predictor of remission. The psychophysiological changes found support the use of gCBT as monotherapy treatment for mild-moderate MDD, corroborate the importance of the observation of the patients in theirs whole sociopsychophysiological condition since they are related to remission outcome and then stimulate further studies of validation of clinical protocols that work on all of these psychophysiological domains studied. Trial Registration U1111–1215-4472. Registered 21 August 2018, http://www.ensaiosclinicos.gov.br/rg/RBR-3npbf8/.
KW - Anxiety
KW - Cortisol
KW - Open-label trial
KW - Self-esteem
KW - Sleep
UR - http://www.scopus.com/inward/record.url?scp=85100722958&partnerID=8YFLogxK
U2 - 10.1007/s12144-020-01324-9
DO - 10.1007/s12144-020-01324-9
M3 - Article
AN - SCOPUS:85100722958
SN - 1046-1310
VL - 42
SP - 592
EP - 601
JO - Current Psychology
JF - Current Psychology
IS - 1
ER -